Specify a stock or a cryptocurrency in the search bar to get a summary
Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems. It provides its products under Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India. Address: Plot No. P-1 and P-2, Pune, India, 411057
Analytics
WallStreet Target Price
132 977.79 INRP/E ratio
54.2911Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EMCURE
Dividend Analytics EMCURE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EMCURE
Stock Valuation EMCURE
Financials EMCURE
Results | 2019 | Dynamics |